Vizgen Revenue and Competitors
Estimated Revenue & Valuation
- Vizgen's estimated annual revenue is currently $35M per year.
- Vizgen's estimated revenue per employee is $154,000
Employee Data
- Vizgen has 227 Employees.
- Vizgen grew their employee count by 40% last year.
Vizgen Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $3.4M | 30 | -21% | N/A | N/A |
#2 | $2.7M | 28 | N/A | N/A | N/A |
#3 | $4M | 36 | 0% | N/A | N/A |
#4 | $55.3M | 311 | 14% | N/A | N/A |
#5 | $1.5M | 18 | 13% | N/A | N/A |
#6 | $1M | 12 | 0% | N/A | N/A |
#7 | $3.7M | 33 | N/A | N/A | N/A |
#8 | $0.6M | 18 | 38% | $81.7M | N/A |
#9 | $7.1M | 58 | 9% | $1.5M | N/A |
#10 | $0.3M | 4 | N/A | N/A | N/A |
What Is Vizgen?
Vizgen is the life sciences company developing the next generation of Spatially Resolved Transcriptomics. The Company's proprietary MERFISH (multiplexed error-robust fluorescence in situ hybridization) technology enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and detection efficiency at subcellular resolution. The high throughput and resolution and the low cost per cell achieved by the technology enables a wide range of tissue-scale basic research and translational medicine and is instrumental to efforts to discover and map cell types and states in a range of tissues and organisms. MERFISH is used as a tool for several Human Cell Atlas projects and was named a “Technology to Watch in 2018†by Nature. Tools employing MERFISH help to advance data-driven drug discovery and development and enable new insights for clinical pathology and diagnostics. “Vizgen's MERFISH technology undoubtedly will emerge as the next-gen platform for high-resolution spatial biology,†said Dr. David R. Walt, Co-founder of Vizgen; Hansjörg Wyss Professor of Biologically Inspired Engineering, Harvard Medical School; Professor of Pathology, Brigham and Women's Hospital; Core Faculty, Wyss Institute for Bioinspired Engineering, Harvard University; HHMI Professor. “It enables comprehensive transcriptomics combined with proteomics and has both whole tissue and subcellular resolution. It checks all the boxes.â€
keywords:N/AN/A
Total Funding
227
Number of Employees
$35M
Revenue (est)
40%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Vizgen News
In addition to the company's poster presentation at AACR, Vizgen showcased preliminary data performing in situ single-cell transcriptomic...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $36.2M | 227 | 21% | N/A |
#2 | $52.7M | 228 | 53% | N/A |
#3 | $44.8M | 231 | 0% | $132.9M |
#4 | $55.9M | 231 | 26% | N/A |
#5 | $42.4M | 232 | 15% | $16.9M |